When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EPZM - Epizyme down 3% after filing tazemetostat NDA for epithelioid sarcoma
Epizyme Inc.
Epizyme (EPZM-3.3%) slips on modestly higher volume after announcing that the FDA has accepted for review its marketing application seeking accelerated approval for tazemetostat for the treatment of epithelioid sarcoma. As is typical for a filing like this, the bulk of the supporting efficacy data were generated in a Phase 2 study.
More news on: Epizyme, Inc., Healthcare stocks news, Stocks on the move,